Takeda and Protagonist Therapeutics, Inc. Enter into Worldwi

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

libyannewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from libyannewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Osaka , Cambridge , Cambridgeshire , United Kingdom , United States , American , Dineshv Patel , Ann Hematol , Julie Kim , Us Co , Japan Ministry Of Health , European Medicines Agency , Takeda Pharmaceutical Company Limited , Drug Administration , Takeda Pharmaceuticals United Statesa Inc , Exchange Commission , Protagonist Therapeutics Inc , Nasdaq , American Society Of Hematology , Be Protagonist Co , Takeda Will Be Protagonist , Commercialization Partner With , With Exclusive Ex U , Commercialize Rusfertide , Polycythemia Vera , Will Make , Upfront Payment , Combines Protagonist , Commercial Expertise , Plus Year Legacy , Driving Innovation Within , Rare Hematology , Host Conference Call , Webcast Today , Protagonist Therapeutics , American Society , Orphan Drug Designation , Fast Track , Rare Pediatric Disease , Rare Pediatric Disease Voucher , Specific Populations , Takeda Pharmaceuticals United Statesa , Prescribing Information , Leuk Lymphoma , Englj Med , Annual Report , Therapeutics Cautionary Note , Private Securities Litigation Reform Act ,